ライフサイエンスコーパス: arabinoside

1 ese drugs) or greater than 7.5 g of cytosine arabinoside.

2 ) on days 1, 3, and 5 combined with cytosine arabinoside.

3 abolished by treatment with cytosine beta-d-arabinoside.

4 fter treatment with doxorubicin and cytosine arabinoside.

5 ypic cerebellar cultures exposed to cytosine arabinoside.

6 bonucleosides, and to a lesser extent purine arabinosides.

7 d IV CI over 24 hours, days 1 to 4; cytosine arabinoside 1.5 g/m2/d IV over 2 hours on day 5).

8 (18)F-fluoroazomycin arabinoside ((18)F-FAZA) is a PET tracer of tumor hypoxi

9 specific hypoxia tracer (18)F-fluoroazomycin arabinoside ((18)F-FAZA) over commonly used (18)F-FDG in

10 tanidazole [(18)F-HX4], (18)F-fluoroazomycin arabinoside [(18)F-FAZA], and (64)Cu-diacetyl-bis(N4-met

11 duction courses of dexamethasone, cytarabine arabinoside, 6-thioguanine, etoposide, daunorubicin (DCT

12 C-galactoside-8-C-arabinoside & apigenin-6-C-arabinoside-8-C-galactoside, and 9,12,13-trihydroxy-tran

13 nificantly increased sensitivity to cytosine arabinoside, accompanied by significantly decreased expr

14 nsitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MIP-1alpha could indu

15 I randomized trial of standard dose cytosine arabinoside and daunomycin + rhG-CSF).

16 gistically enhanced cytotoxicity of cytosine arabinoside and doxorubicin in AML blasts but not in nor

17 emotherapeutic induction regimen of cytosine arabinoside and idarubicin hydrochloride, with regressio

18 0 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults

19 treating the neurons with combined cytosine arabinoside and NGF withdrawal, we demonstrate that Q97

20 de, delphinidin-3-galactoside, delphinidin-3-arabinoside and petunidin-3-arabinoside were twice as bi

21 rapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a variety of

22 ence of the DNA synthesis inhibitor cytosine arabinoside and transfected with plasmids containing the

23 nts lack cell-wall associated hydroxyproline arabinosides and can be rescued with exogenous cellulose

24 guous Hyp and a corresponding mixture of Hyp-arabinosides and Hyp-polysaccharides.

25 tachment sites for arabino-oligosaccharides (arabinosides) and clustered, non-contiguous Hyp residues

26 chemotherapeutic agents etoposide, cytosine arabinoside, and Adriamycin.

27 Peonidin-3-O-galactoside, cyanidin-3-O-arabinoside, and cyanidin-3-O-galactoside were the predo

28 enced by blocking neurogenesis with cytosine arabinoside, and helps to preserve the hippocampal funct

29 thylprednisolone, High-dose Ara-C = cytosine arabinoside, and Platinum = cisplatinum), in a group of

30 y-Moser isomers apigenin-6-C-galactoside-8-C-arabinoside & apigenin-6-C-arabinoside-8-C-galactoside,

31 295 was compared to the response to cytosine arabinoside (Ara C) and correlated with the presence or

32 ce to the cytotoxic adenosine analog adenine arabinoside (Ara-A).

33 ro sensitivity of DS myeloblasts to cytosine arabinoside (ara-C) and daunorubicin and the greater gen

34 Cytosine arabinoside (ara-C) and gemcitabine (dFdC) are two stand

35 phonate derivatives of cytidine and cytosine arabinoside (ara-C) have been prepared via phosphite add

36 Cytosine arabinoside (ara-C) is a cytidine analog that incorporat

37 Cytarabine arabinoside (ara-C) is an antimetabolite used to treat h

38 with non-DS AML, linked to greater cytosine arabinoside (ara-C) sensitivity and higher transcript le

39 y de novo or acquired resistance to cytosine arabinoside (Ara-C), a primary component of induction ch

40 erebroventricular (ICV) infusion of cytosine arabinoside (Ara-C), an inhibitor for cell proliferation

41 -phosphono derivatives of cytidine, cytosine arabinoside (ara-C), and uridine have been prepared via

42 4B conferred leukemic resistance to cytosine arabinoside (ara-C), daunorubicin, and etoposide.

43 o treatments with daunomycin (DNR), cytosine arabinoside (ARA-C), or gamma irradiation (RAD).

44 n to the standard chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific to leukem

45 s, exhibited up to 1.7-fold reduced cytosine arabinoside (ara-C)-induced apoptosis, compared with moc

46 2-Chlorodeoxyadenosine (2-CdA), or cytosine arabinoside (ARA-C).

47 yurea (HU), daunorubicin (DNR), and cytosine arabinoside (Ara-C).

48 esponse to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been inves

49 Exposure to low-dose cytosine arabinoside (Ara-C; 10 nmol/L) increased hemoglobin leve

50 chemotherapy regimens consisting of cytosine arabinoside (Ara-C; A), daunorubicin (D), and etoposide

51 cancer and antiviral agents such as cytosine arabinoside (araC) and gemcitabine.

52 stigation of DNA-damaging agents to cytosine arabinoside (AraC) and UV irradiation.

53 Cytosine arabinoside (araC) is an important drug used for the tre

54 were then treated with either beta-cytosine arabinoside (araC) or caffeine, and chromatid breaks wer

55 We evaluated the delivery of 14C-cytosine arabinoside (AraC) to rat brain by: 1) intravenous (IV)

56 f DNA synthesis with hydroxyurea or cytosine arabinoside (AraC) triggers a concerted repression of hi

57 neurons, we compared the effects of cytosine arabinoside (AraC), a known neuronal apoptosis inducer,

58 ty experiments with 5-fluorouracil, cytosine arabinoside (araC), and mercaptopurine (MP) demonstrated

59 found by others that treatment with cytosine arabinoside (araC), but not aphidicolin, can also phenoc

60 ary were treated with pro-apoptotic cytosine arabinoside (araC), PP1alpha protein increased twofold a

61 We recently reported that cytosine arabinoside (AraC)-induced apoptosis of cerebellar neuro

62 s aryl-glycosides (beta-D-fucosides, alpha-L-arabinosides, beta-D-glucosides, beta-D-galactosides, be

63 operoxide or the anti-cancer agents cytosine arabinoside, bleomycin, melphalan, and cis-dichlorodiamm

64 rapeutic agents [i.e. methotrexate, cytosine arabinoside (both free and liposomal) and thio-tetraethy

65 nd in F. vesca fruits, such as taxifolin 3-O-arabinoside (both) and peonidin 3-O-malonylglucoside (Ru

66 -Hyp(4))(n) fusion glycoproteins yielded Hyp-arabinosides but no Hyp-polysaccharide.

67 ls to resistance against puromycin, cytosine arabinoside, colcemid, and methotrexate.

68 alone) or intensive (mitoxantrone, cytosine arabinoside, cyclophosphamide) priming on the cytogeneti

69 body irradiation before etoposide, cytoside arabinoside, cyclophosphamide, and methylprednisolone.

70 h high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, c

71 2'-difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a class of nuc

72 th standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE).

73 e BFU-e's from apoptosis induced by cytosine arabinoside, demonstrating that the SP600125 inhibited p

74 More importantly, cytosine arabinoside, ethidium bromide, 5-azacytidine and aspirin

75 phenolic compounds, including taxifolin 3-O-arabinoside, glycosides of quercetin, kaempferol, cyanid

76 sis during a synchronous infection, cytosine arabinoside had no effect at concentrations sufficient t

77 us an anthracycline with or without cytosine-arabinoside has yielded complete response rates of 85% o

78 ves of the nucleosides cytidine and cytosine arabinoside have been prepared from the corresponding nu

79 without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously administered, in similar

80 123I-Labeled iodoazomycin arabinoside (IAZA) is a marker of hypoxia in vivo.

81 The addition of cytosine arabinoside improves outcome still further.

82 as well as that of HHT and low-dose cytosine arabinoside in patients failing IFN-alpha therapy.

83 C promoted apoptosis and sensitized cytosine arabinoside-induced apoptosis in OCI-AML3 cells.

84 an leukemic cells more resistant to cytosine arabinoside-induced apoptosis, whereas knockdown of GRP7

85 kinase inhibitor CEP-1347 prevented cytosine arabinoside-induced neuronal death, demonstrating that t

86 f immature granule cells induced by cytosine arabinoside is not inhibited by the Egr inhibitor constr

87 Cytarabine (cytosine arabinoside) is one of the most effective drugs for the

88 thocyanins mono-galactoside, -glucoside and -arabinoside isomers of delphinidin, cyanidin, petunidin,

89 oxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp874 by caspases.

90 10% with the BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) protocol.

91 onditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d on days

92 Adenine-5'-arabinoside monophosphate (Ara-AMP [vidarabine]), ribavi

93 line hydroxylation and hydroxyproline-linked arabinosides, on a mucin (MUC1)-derived substrate, was a

94 ent of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with

95 troimidazole PET tracer (18)F-fluoroazomycin arabinoside (or (18)F-1-alpha-D-[5-fluoro-5-deoxyarabino

96 toside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, petunidin-3-O-glucoside, pelargonidin-3-O-g

97 ns gave ratios of Hyp-polysaccharides to Hyp-arabinosides plus non-glycosylated Hyp consistent with t

98 hen combined with either ABT-737 or cytosine arabinoside, provided substantial therapeutic benefit in

99 flavonoids as rutin pentoside, quercetin-3-O-arabinoside, quercetin glycogallate, quercetin-3-O-rhamn

100 in-3-O-glucoside (quercitrin), quercetin-3-O-arabinoside, quercetin glycohydroxybenzoate, quercetin g

101 nt with PI3K/AKT as an effector for cytosine arabinoside resistance in acute myeloid leukemia, overex

102 eta-D-galactosides, beta-L-xylosides, beta-D-arabinosides), similar to the native enzyme.

103 PI3-kinase inhibitor, LY294002, and cytosine arabinoside synergized in antileukemia effects on Meg-01

104 three known antitrypanosomal agents adenine arabinoside, tubercidin, and cordycepin, or they need to

105 d by potassium deprivation, but not cytosine arabinoside, we asked whether the Egr inhibitor acts by

106 e, delphinidin-3-arabinoside and petunidin-3-arabinoside were twice as bioaccessible in fed state, wh

107 din-3-(6''-acetoyl)-glucoside and malvidin-3-arabinoside were twice as bioaccessible under fasted con

108 Treatment of cells with cytosine arabinoside, which blocks the late buildup of dsRNA in v

109 nosylation adds short oligoarabinosides (Hyp-arabinosides) while galactosylation leads to the additio

110 AraC was metabolized into uracil arabinoside within the brain.